Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Liver CancerColorectal Cancer Liver Metastases
Interventions
DEVICE

Multi-mode tumor treatment system

The intervention for this arm involves the use of a novel multi-mode tumor treatment system, developed by Shanghai MAaGI Medical Technology Co., Ltd. The system combines cryoablation and radiofrequency ablation in a single device. During the treatment, the tumor tissue is rapidly frozen to create an ice ball larger than the lesion by 5mm, followed by thawing and rewarming. Subsequently, the lesion is treated with radiofrequency ablation according to conventional procedures to ensure complete ablation within a safety margin of 5-10mm around the tumor.

DEVICE

Radiofrequency ablation therapeutic apparatus

The intervention for this arm involves the use of conventional radiofrequency ablation equipment, which is developed by MedSphere International (Shanghai) Co., Ltd.. During the treatment, the tumor is ablated using predefined power and time settings to ensure complete ablation within a safety margin of 5-10mm around the tumor.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER